Angel Biomedical Ltd announces supply agreement (3237D)
15 5월 2012 - 3:00PM
UK Regulatory
TIDMABH
RNS Number : 3237D
Angel Biotechnology Holdings Plc
15 May 2012
15 May 2012
Angel Biotechnology Holdings plc
("Angel" or "the Group")
Angel Biomedical Ltd announces manufacturing supply
agreement
with Cardium Therapeutics for Excellagen(R)
Angel Biomedical Limited, a subsidiary of Angel Biotechnology
Holdings plc (AIM: ABH), a global biopharmaceutical contract
manufacturer, is pleased to announce an agreement with Cardium
Therapeutics (NYSE Amex: CXM). The contract value will be in excess
of GBP400,000 over the initial 12 month period, and will cover the
manufacture of formulated collagen for Cardium's Excellagen(R)
product, which has recently been cleared for marketing by the U.S.
Food and Drug Administration (FDA). Excellagen is a
professional-use high molecular weight fibrillar bovine Type I
topical gel (2.6%) specifically engineered as an adjunct to
debridement for the management of diabetic foot ulcers and other
dermal wounds.
In addition to the manufacturing of Excellagen's formulated
collagen, Angel Biomedical will assist Cardium to facilitate filing
for a CE Mark for Excellagen for marketing and sale in the European
Union and in other countries recognizing CE Mark approval.
Additionally, Angel Biomedical will assist Cardium in establishing
its own Device Master File with the FDA's Center for Devices and
Radiological Health covering the process for manufacturing the
Company's Excellagen formulated fibrillar collagen gel.
Christopher J. Reinhard, Chairman and CEO of Cardium
Therapeutics said "We are pleased to announce the agreement with
Angel Biomedical following Angel's recent asset purchase of a
collagen manufacturing facility located in Glasgow, Scotland. This
new agreement is a logical next step that provides for a
continuation of the specialized formulated collagen supply that is
needed to support Excellagen's commercialization activities".
Dr. Stewart White, Acting Chief Executive Officer of Angel
Biotechnology said "We are excited by this new partnership with
Cardium, to provide formulated high molecular weight collagen. We
now look forward to continuing this important relationship for the
commercial manufacture of Cardium's new FDA-cleared Excellagen
advanced wound care product and to facilitate its CE marking to
assist Cardium expand its global distribution opportunities,".
For further information:
Angel Biotechnology Holdings plc
Stewart White, Commercial Director, Acting CEO
www.angelbio.com
Lorna Peers, Finance Director +44 (0) 131 445 6077
Grant Thornton, Corporate Finance
Colin Aaronson / Melanie Frean +44 (0) 20 7383 5100
Hybridan LLP (Broker)
Claire Noyce, Deepak Reddy +44 (0) 20 7947 4350
Media enquiries:
The Communications Portfolio Ltd
Ariane Comstive / Caolan Mahon +44 (0) 20 7536 2028 / 2029
ariane.comstive@communications-portfolio.co.uk
Notes to Editors:
Angel Biotechnology Holdings plc is a full service contract
bio-manufacturing partner to biotechnology and pharmaceutical
companies worldwide. Angel specialises in advanced biologics
including biopharmaceutical proteins and cell therapies, such as
cellular vaccines and stem cells. At present, Angel's products are
principally used in pre-clinical studies and clinical trials with a
view to becoming the contract manufacturer of choice on a
continuing basis.
Drug development companies outsource their biopharmaceutical
manufacturing requirements to Angel to reduce their own capital
requirements and enable them to develop products more rapidly. In
addition, Angel provides complete regulatory services and
documentation to its customers while its manufacturing processes
adhere to the most stringent regulatory requirements. Products are
produced to current Good Manufacturing Practice (cGMP) standards as
required by the US Food and Drug Administration (FDA), and in
facilities that are certified to European standards by the
Medicines and Healthcare products Regulatory Agency (MHRA).
Its customers range from early-stage biotechnology companies
including ReNeuron plc and US-based Pathfinder Cell Therapy, to
established pharmaceutical companies such as Russian-based Materia
Medica Holdings.
The Angel Group has three facilities: Pentlands Science Park
near Edinburgh where it employs 38 people, Cramlington, near
Newcastle-upon-Tyne, which is expected to employ up to 10 people by
the end of 2012 and the newly announced facility in Glasgow.
More information is available at www.angelbio.com .
- Ends -
This information is provided by RNS
The company news service from the London Stock Exchange
END
AGRBRGDUSXBBGDS
Angel Biotechnology (LSE:ABH)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Angel Biotechnology (LSE:ABH)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024
